Could cholinesterase inhibitors and memantine alleviate HIV dementia? [3]

Journal of Acquired Immune Deficiency Syndromes

Volumn 38, Issue 1, 2005, Pages 113-114

  Alisky, Joseph Martin ^a  

^a MARSHFIELD CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; RIVASTIGMINE;

ALZHEIMER DISEASE; ATTENTION DEFICIT DISORDER; BRAIN INJURY; CHOLINERGIC ACTIVITY; CLINICAL TRIAL; DEMENTIA; DRUG EFFECT; DRUG POTENTIATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; MULTIINFARCT DEMENTIA; MULTIPLE SCLEROSIS; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RECEPTOR BLOCKING;

AIDS DEMENTIA COMPLEX; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHOLINESTERASE INHIBITORS; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; MEMANTINE;

EID: 11844257529     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200501010-00021     Document Type: Letter

References (23)

1. Robertson KR, Robertson WT, Ford S, et al. Highly active antiretroviral therapy improves neurocognitive functioning. J Acquir Immune Defic Syndr. 2004;36:562-566.
2. Gimenez F, Fernandez C, Mabondzo A. Transport of HIV protease inhibitors through the blood-brain barrier and interactions with the efflux proteins, P-glycoprotein and multidrug resistance proteins. J Acquir Immune Defic Syndr. 2004;36:649-658.
3. Kusanda L, McGuire D, Pulliam L. Changes in monocyte/macrophage neurotoxicity in the era of HAART: implications for HIV-associated dementia. AIDS. 2002;16:31-38.
4. Valcour V, Shikuma CM, Watters MR, et al. Cognitive impairment in older HIV-1 sero-positive individuals: prevalence and potential mechanisms. AIDS. 2004;18(Suppl 1):79-86.
5. Lazarini F, Seilhean D, Rosenblum O, et al. Human immunodeficiency virus type 1 DNA and RNA load in brains of demented and non-demented patients with acquired immunodeficiency syndrome. J Neurovirol. 1997;3:299-303.
6. Wilkinson DG, Francis PT, Schwann E, et al. Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy. Drugs Aging. 2004;21:453-478.
7. Greene YM, Tariot PN, Wishart H, et al. A 12-week, open trial of donepezil hydrochloride in patients with multiple sclerosis and associated cognitive impairments. J Clin Psychopharmacol. 2000;20:350-356.
8. Aarsland D, Hutchinson M, Larsen JP. Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia. Int J Geriatr Psychiatry. 2003;18:937-941.
9. Wilens TE, Biederman J, Wong J, et al. Adjunctive donepezil in attention deficit hyperactivity disorder youth: case series. J Child Adolesc Psychopharmacol. 2000;10:217-222.
10. Zhang L, Plotkin RC, Wang G, et al. Cholinergic augmentation with donepezil enhances recovery in short-term memory and sustained attention after traumatic brain injury. Arch Phys Med Rehabil. 2004;85:1050-1055.
11. Masanic CA, Bayley MT, VanReekum R, et al. Open-label study of donepezil in traumatic brain injury. Arch Phys Med Rehabil. 2001;82:896-901.
12. Morey CE, Cilo M, Berry J, et al. The effect of aricept in persons with persistent memory disorder following traumatic brain injury: a pilot study. Brain Inj. 2003;17:809-815.
13. Whelan FJ, Walter MS, Schultz SK. Donepezil in the treatment of cognitive dysfunction associated with traumatic brain injury. Ann Clin Psychiatry. 2000;12:131-135.
14. Erkinjuntti T, Roman G, Gauthier S. Treatment of vascular dementia: evidence from clinical trials with cholinesterase inhibitors. Neurol Res. 2004;26:603-605.
15. Moretti R, Torre P, Antonello RM, et al. Rivastigmine in subcortical vascular dementia: a randomized, controlled open 12-month study in 208 patients. Am J Alzheimers Dis Other Demen. 2003;18:265-272.
16. Erkinjuntti T, Roman G, Gautheir S, et al. Emerging therapies for vascular dementia and vascular cognitive impairment. Stroke. 2004;35:1010-1017.
17. Langford TD, Letendre SL, Marcotte TD, et al. Severe, demyelinating leuko-encephalopathy in AIDS patients on antiretroviral therapy. AIDS. 2002;16:1019-1029.
18. Lipton SA. Memantine prevents HIV coat protein-induced neuronal injury in vitro. Neurology. 1992;42:1403-1405.
19. Muller WE, Pergande G, Ushijima H, et al. Neurotoxicity in rat cortical cells caused by N-methyl-D-aspartate (NMDA) and gp120 of HIV-1: induction and pharmacological intervention. Prog Mol Subcell Biol. 1996;16:44-57.
20. Toggas SM, Masliah E, Mucke L. Prevention of HIV-1 gp120-induced neuronal damage in the central nervous system of transgenic mice by the NMDA receptor antagonist memantine. Brain Res. 1996;706:303-307.
21. Manji H, Miller R. The neurology of HIV infection. J Neurol Neurosurg Psychiatry. 2004;75(Suppl 1):i29-i35.
22. Reisberg B, Doody R, Stoffler A, et al. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003;348:1333-1341.
23. Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer's disease already receiving donepezil: a randomized controlled trial. JAMA. 2004;291:317-324.